Document is current

Any future updates will be listed below

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0356

Published Online: 2020-11-09

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark